Time-dependent cytokine and chemokine changes in mouse cerebral cortex following a mild traumatic brain injury

  1. David Tweedie  Is a corresponding author
  2. Hanuma Kumar Karnati
  3. Roger Mullins
  4. Chaim G Pick
  5. Barry J Hoffer
  6. Edward J Goetzl
  7. Dimitrios Kapogiannis
  8. Nigel H Greig
  1. National Institute on Aging, NIH, United States
  2. Sackler School of Medicine, Tel-Aviv University, Israel
  3. Case Western Reserve University, United States
  4. University of California Medical Center, United States

Abstract

Traumatic brain injury (TBI) is a serious global health concern, many individuals live with TBI-related neurological dysfunction. A lack of biomarkers of TBI has impeded medication development. To identify new potential biomarkers, we time-dependently evaluated mouse brain tissue and neuronally derived plasma extracellular vesicles proteins in a mild model of TBI with parallels to concussive head injury. Mice (CD-1, 30–40 g) received a sham procedure or 30 g weight-drop, and were euthanized 8, 24, 48, 72, 96 hours, 7, 14 and 30 days later. We quantified ipsilateral cortical proteins. Many of them differed from 8 hours onwards post mTBI compared to sham, 23 proteins changed in 4 or more of 8 different time points. Gene ontology pathways mapped from altered proteins over time related to pathological and physiological processes. Further validation of proteins identified in this study may provide utility as treatment response biomarkers.

Data availability

All data generated by US NIH funded research is available to the public, the data generated in this study is available to the public. The data used to generate the Figures in the manuscript are provided as source data files.

Article and author information

Author details

  1. David Tweedie

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    For correspondence
    tweedieda@grc.nia.nih.gov
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8446-4544
  2. Hanuma Kumar Karnati

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Roger Mullins

    Laboratory of Clinical Investigation, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Chaim G Pick

    Department of Anatomy and Anthropology, Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
    Competing interests
    The authors declare that no competing interests exist.
  5. Barry J Hoffer

    Department of Neurological Surgery, Case Western Reserve University, Cleveland, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Edward J Goetzl

    Department of Medicine, University of California Medical Center, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Dimitrios Kapogiannis

    Laboratory of Clinical Investigation, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Nigel H Greig

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3032-1468

Funding

National Institutes of Health (AG000944)

  • Nigel H Greig

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Brandon K Harvey, NIDA/NIH, United States

Ethics

Animal experimentation: AlI animal studies were conducted at the Intramural Research Program of the National Institute on Aging, Baltimore, MD, USA. Experimental animal protocols were approved by the Animal Care and Use Committee of the Intramural Research Program, National Institute on Aging (438-TGB-2022) and were in compliance with the guidelines for animal experimentation of the National Research Council (Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011) and the National Institutes of Health (DHEW publication 85-23, revised, 1995).

Version history

  1. Received: February 6, 2020
  2. Accepted: August 14, 2020
  3. Accepted Manuscript published: August 17, 2020 (version 1)
  4. Accepted Manuscript updated: August 21, 2020 (version 2)
  5. Version of Record published: September 4, 2020 (version 3)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,473
    Page views
  • 333
    Downloads
  • 21
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David Tweedie
  2. Hanuma Kumar Karnati
  3. Roger Mullins
  4. Chaim G Pick
  5. Barry J Hoffer
  6. Edward J Goetzl
  7. Dimitrios Kapogiannis
  8. Nigel H Greig
(2020)
Time-dependent cytokine and chemokine changes in mouse cerebral cortex following a mild traumatic brain injury
eLife 9:e55827.
https://doi.org/10.7554/eLife.55827

Share this article

https://doi.org/10.7554/eLife.55827

Further reading

    1. Developmental Biology
    2. Immunology and Inflammation
    Amir Hossein Kayvanjoo, Iva Splichalova ... Elvira Mass
    Research Article

    During embryogenesis, the fetal liver becomes the main hematopoietic organ, where stem and progenitor cells as well as immature and mature immune cells form an intricate cellular network. Hematopoietic stem cells (HSCs) reside in a specialized niche, which is essential for their proliferation and differentiation. However, the cellular and molecular determinants contributing to this fetal HSC niche remain largely unknown. Macrophages are the first differentiated hematopoietic cells found in the developing liver, where they are important for fetal erythropoiesis by promoting erythrocyte maturation and phagocytosing expelled nuclei. Yet, whether macrophages play a role in fetal hematopoiesis beyond serving as a niche for maturing erythroblasts remains elusive. Here, we investigate the heterogeneity of macrophage populations in the murine fetal liver to define their specific roles during hematopoiesis. Using a single-cell omics approach combined with spatial proteomics and genetic fate-mapping models, we found that fetal liver macrophages cluster into distinct yolk sac-derived subpopulations and that long-term HSCs are interacting preferentially with one of the macrophage subpopulations. Fetal livers lacking macrophages show a delay in erythropoiesis and have an increased number of granulocytes, which can be attributed to transcriptional reprogramming and altered differentiation potential of long-term HSCs. Together, our data provide a detailed map of fetal liver macrophage subpopulations and implicate macrophages as part of the fetal HSC niche.

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Yuting Zhang, Min Zhang ... Guojiang Chen
    Research Article

    Marburg virus (MARV) is one of the filovirus species that cause deadly hemorrhagic fever in humans, with mortality rates up to 90%. Neutralizing antibodies represent ideal candidates to prevent or treat virus disease. However, no antibody has been approved for MARV treatment to date. In this study, we identified a novel human antibody named AF-03 that targeted MARV glycoprotein (GP). AF-03 possessed a high binding affinity to MARV GP and showed neutralizing and protective activities against the pseudotyped MARV in vitro and in vivo. Epitope identification, including molecular docking and experiment-based analysis of mutated species, revealed that AF-03 recognized the Niemann-Pick C1 (NPC1) binding domain within GP1. Interestingly, we found the neutralizing activity of AF-03 to pseudotyped Ebola viruses (EBOV, SUDV, and BDBV) harboring cleaved GP instead of full-length GP. Furthermore, NPC2-fused AF-03 exhibited neutralizing activity to several filovirus species and EBOV mutants via binding to CI-MPR. In conclusion, this work demonstrates that AF-03 represents a promising therapeutic cargo for filovirus-caused disease.